[1]
I. Kaczorowska-Kossowska, “Admissibility of Using the Medicinal Products that Have Not Been Authorised in National Procedure”, P&W, no. 2 (40), pp. 30–44, Jul. 2022, doi: 10.36128/priw.vi40.256.